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aBstraCt
introduCtion. The aim of this study is to present the efficacy and safety of non-penetrating phaco-deep sclerecto-
my (PDS) with implantation of an absorbable sodium hyaluronate implant (SkGel/Corneal). 
MATERIALS AND METHODS. In a prospective case series study 219 procedures were performed on 176 sub-
jects receiving PDS with SkGel implantation. Indications were uncontrolled primary-open angle glaucoma 
(POAG) and operable cataract. Data collected included best corrected visual acuity (BCVA), intraocular 
pressure (IOP), and number of hypotensive medications. Follow-up examinations were performed one and 
seven days after procedure, then one, three, and six months after, and thereafter every six months. Complete 
and qualified success (without and with hypotensive medications) was assessed for IOP ≤ 18 mm Hg and 
IOP ≤ 12 mm Hg.
resuLts. The mean follow-up was 48.3 ± 12.8 months. At 24 months, mean IOP decreased from 19.9 ± 5.0 mm 
Hg to 13.4 ± 3.1 mm Hg (P < 0.001) (31.8% reduction) and to 13.3 ± 2.7 mm Hg (P = 0.003) and after 60 months 
(33.2% reduction). At the 24-month follow-up, the average number of anti-glaucoma medications was reduced from 
2.3 ± 0.8 to 0.62 ± 0.88 (p < 0.001). Complete and qualified success rates for IOP ≤ 18 mm Hg were 70.1% and 
93.0%, respectively. Goniopuncture (23.8%), suturolysis (20.1%), and needling (18.3%) were performed. The most 
common complication was transient hypotony (36.07%).
ConCLusions. PDS with SkGel leads to an effective decrease in IOP over a long-term follow-up. The profile of the 
complications indicates that it is a safe procedure.
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introduCtion
Non-penetrating deep sclerectomy (DS) avoids 
full thickness perforation of the anterior chamber, 
thus minimising the risk of complications encoun-
tered in classical trabeculectomy [1, 2]. Upon cre-
ation of a deep scleral flap, the external wall of 
Schlemm’s canal is exposed [3]. In order to de-roof 
the Schlemm’s canal wall, thus allowing aqueous 
humour to percolate through the semi-permeable 
trabeculo-Descemet’s membrane (TDM) into the 
intrascleral lake. Here, prolonged absorption of 
aqueous humour filtered from the anterior cham-
ber through the created TDM takes place [3–5]. 
This controlled percolation of aqueous humour from 
the anterior chamber results in intraocular pressure 
(IOP) reduction, while limiting excessive filtration 
to a certain extent, enough to prevent the onset of 
hypotony [3]. The precise mechanism of DS action 
is not yet fully known, but it seems that the newly 
created intrascleral space and relieving the collapse 
of Schlemm’s canal are of key importance to aqueous 
humour percolation through the collector channels 
near the limbus [5]. Various scleral implants are used 
to stabilise the scleral lake, but the superiority of DS 
in combination with these implants compared to the 
classical procedure leaves no doubt at this time [6–10]. 
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The objective of this study is to present the effi-
cacy and safety of PDS with implantation of an ab-
sorbable sodium hyaluronate implant (SkGel/Cor-
neal) in POAG with co-existing cataract based on 
long-term follow-up.
MATERIALS AND METHODS
This prospective case series study was approved 
by the Bioethics Committee of the Military In-
stitute of Medicine in Warsaw, and every patient 
participating in the study gave written consent to 
the procedure a nd follow up.
The indication for surgical treatment was pri-
mary-open angle glaucoma (POAG) refractory to 
maximum medical tolerable therapy with anti-glau-
coma medications, without satisfactory IOP control 
(IOP ≥ 18 mm Hg) or progression and changes to 
the visual field as well as co-existing cataract.
Exclusion criteria: secondary glaucoma, inability 
to provide consent to procedure, previous incisional 
glaucoma surgery, laser trabeculoplasty, pregnancy, 
and breastfeeding period. An improperly prepared 
TDM intraoperative also disqualified the subject 
from the study.
Follow-up examinations included measurement 
of IOP with Goldmann applanation tonometry, 
evaluation of the anterior and posterior segments 
of the eye, and careful evaluation of post-operative 
complications. The number of glaucoma medica-
tions used and the type and frequency of post-oper-
ative procedures to re-stablish drainage paths were 
analysed. BCVA was tested on a Snellen chart and 
then converted to the logMAR scale. The schedule 
of visits included a pre-operative baseline exam, 
surgery, post-operative visits on days one and seven, 
then months one, three, six, and 12, and then every 
six months.
All surgical procedures were carried out by a sin-
gle surgeon (MR) using the previously described 
technique [8]. First the conjunctiva was separated 
from the corneal limbus, then a 5 × 5 mm surface 
scleral flap as thin as possible was created, with its 
base in the limbus area. Using the modified meth-
od of Bellucci et al. [11], a 3.5 × 3.5 × 0.75 mm, 
piece of sclera was excised in the deep layer of the 
sclera approaching the scleral spur. The next stage of 
the procedure, phacoemulsification, was performed 
through a temporal clear corneal incision, 2.6 mm 
in width, and a flexible intraocular lens implant 
was inserted into the anterior chamber (SA30AT, 
SA60AT, SN60AT, SN60WF — Alcon Laborato-
ries). In the final step of the procedure, Schlemm’s 
canal and Descemet’s membrane were exposed up 
to Schwalbe’s line, and a deep scleral flap up to 
Schwalbe’s line in the exterior wall of Schlemm’s ca-
nal was removed (Fig. 1A). Next, the SkGel implant 
(Corneal) was inserted into the scleral bed (Fig. 1B), 
and the surface flap and wound in the conjunctiva 
were closed.
Symptoms of inflammation and fibrosis of the 
filtering bleb were treated with fluorouracil (5-FU) 
subconjunctivally (5 mg, 0.1 mL) injected daily for 
five consecutive days, and this was repeated when 
necessary after one week. In cases where good IOP 
regulation was achieved antimetabolites were discon-
tinued, or when a typical complication occurred [8]. 
At the same time, suturolysis of one or two sutures 
of the scleral flap were performed using an argon 
laser (50 µm, 800–1000 mW, 100 ms). In the case 
of increased IOP (> 15 mm Hg), caused by failure 
of the filtering membrane (lack of or poorly devel-
oped filtering bleb), goniopuncture was performed 
(TDM perforation) using an Nd:YAG laser (2–4 mJ, 
2–15 impulses) [7]. If IOP lowering was not suffi-
cient, delicate eye massage was applied. Superficial 
needling was applied when Tennon’s encapsulation 
occurred while filtration under the flap was observed. 
Deep needling, however, was performed after UBM 
examination demonstrated the presence of a scleral 
lake and absence of the filtering bleb. All patients 
received a topical steroid in combination with an 
antibiotic (dexamethasone, neomycin, polymyxin B).
Complete success was defined as IOP ≤ 18 mm 
Hg without anti-glaucoma medications and qual-
ified success as IOP ≤ 18 mm Hg with and with-
out anti-glaucoma medications [12]. The same was 
done for the IOP ≤ 12 mm Hg. The procedure was 
recognised as a failure if IOP was above18 mm Hg 
with anti-glaucoma medications, the need for sec-
ond glaucoma surgery, or loss of light perception.
Post-operative complications were divided into 
early (up to one week after surgery) and later (more 
than one week after surgery). Hypotony was rec-
ognised if IOP ≤ 6 mm Hg persisted longer than 
one week; IOP > 18 mm Hg within the first week 
post-surgery was considered elevated [13]. Shallow-
ing of the chamber, displacement of the anterior 
chamber, leaks in the filtering bleb, detachment of 
the choroid, anterior chamber hyphaemia, 3 or 4+ 
of Tyndall effect, and haemorrhagic choroidal de-
tachment were defined according to previously de-
scribed definitions [7, 13]. Deterioration of vision 
was recognised by loss of BCVA by 2 lines or more, 
Katarzyna Lewczuk et al., Non-penetrating phaco-deep sclerectomy with SkGel implantation
117www.journals.viamedica.pl/ophthalmology_journal
Table 1. Patients’ demographic data
Demographic data Mean (SD)
Observation period (months) 48.3 ± 12.8
Age (years) 77.4 ± 11.9
Patients (number) 176
   Female 99
   Male 77
Eyes (number) 219
   Right 109
   Left 110
SD — standard deviation
Figure 1. Non-penetrating deep sclerectomy. Making of the trabeculo-Descemet’s membrane (a); SkGel/Corneal in decompression 
space (B)
and persisting for more than three months after sur-
gery. Statistical processing was carried out according to 
the World Glaucoma Association Guidelines on De-
sign and Reporting of Glaucoma Surgical Trials [13].
Statistical analysis was conducted by means of 
Shapiro-Wilk W-test and Levene’s test, as well as 
Wilcoxon’s signed rank test and Friedman’s ANOVA. 
Survival analysis was conducted using the Ka-
plan-Meier method and the log rank test. Research 
material was gathered in a database created in Ac-
cess, then prepared in Excel from the Microsoft 
Office Professional 2010 package. Statistica PL 
10.0 (StatSoft Polska) software was used for statisti-
cal calculations and creating charts.
resuLts
DEMOGRAPHIC DATA
The study encompassed 219 eyes in 176 subjects 
with POAG and cataract. Demographic data are 
presented in Table 1.
intraoCuLar pressure ControL
Pre-operative baseline mean IOP was 
19.9 ± 5.0 mm Hg and was reduced by 52.5% 
on the first day to 8.5 ± 4.9 mm Hg (P < 0.001). 
Mean IOP stabilised up to one month post-sur-
gery and was not subject to statistically significant 
change until the end of the observation period 
(P = 0.39397). After 12 months of post-operative 
follow-up the mean IOP was 12.7 ± 3.5 mm Hg, 
and after 24 months, 13.4 ± 3.1 mm Hg, which 
was a reduction of mean IOP by 35.4% (P < 0.001) 
and by 31.8% (P < 0.001), respectively. At the 
end of the post-operative observation period (60th 
month), an IOP of 13.3 ± 2.7 mm Hg (P = 0.003) 
was achieved, which resulted in 33.2% reduction. 
(Fig. 2, Tab. 2).
MEDICATIONS
The mean number of anti-glaucoma medica-
tions was reduced from 2.3 ± 0.8 to 0.3 ± 0.7 after 
12 months and to 0.6 ± 0.9 after the 24th month 
post-surgery (P < 0.001). The mean number of an-
ti-glaucoma medications gradually increased from 
0.01 ± 0.15 on the first day to 1.18 ± 1.33 at the 
end of follow-up (Tab. 2).
surgiCaL suCCess
Complete success for the target IOP ≤ 18 mm 
Hg criterion at the 12 and 24 months was achieved 
in 90.5% and in 70.1% of cases, respectively. For 
IOP ≤ 12 mm Hg, the complete success rate was 
lower, amounting to 71.2% at 12 months and 
43.7% at 24 months. The complete success rate 
for the IOP ≤ 18 mm Hg decreased over time 
and reached 39.8% after 36 months, 27.7% after 
48 months, and 12.0% after 60 months, and the 
rate for the target IOP ≤ 12 mm Hg reached 19.3%, 
12.0%, and 3.4%, respectively. Qualified success 
for the IOP ≤ 18 mm Hg criterion after 12 and 
24 months was achieved in 97.3% and 93.0% of cas-
es, respectively, and for the target IOP ≤ 12 mm Hg 
criterion, in 73.8% and 49.3% of cases, respectively. 
a B
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Figure 2. Intraocular pressure values at specific times after surgery
Table 2. Mean and median values, standard deviation, and ranges of intraocular pressure and number of 
medications at specific times after surgery
Time Intraocular pressure [mm Hg] Medications (n)
Mean  
(SD)
Median Range Mean  
(SD)
Median Range
Pre-op 19.9 ± 5.0 19 11–43 2.3 ± 0.8 2 1–5
1st day 8.5 ± 4.9 8 1–39 0.01 ± 0.2 0 0–2
7th day 9.0 ± 4.1 9 1–27 0.01 ± 0.2 0 0–2
1st month 11.8 ± 3.1 11 5–29 0.1 ± 0.3 0 0–2
6th month 11.9 ± 2.9 12 2–22 0.2 ± 0.5 0 0–2
12th month 12.7 ± 3.5 12 5–37 0.3 ± 0.7 0 0–4
18th month 13.5 ± 3.1 13 9–23 0.4 ± 0.7 0 0–3
24th month 13.4 ± 3.1 13 7–23 0.6 ± 0.9 0 0–4
36th month 13.5 ± 3.0 13 4–21 0.9 ± 0.9 1 0–3
48th month 13.2 ± 2.5 13 9–19 1.0 ± 0.9 1 0–3
60th month 13.3 ± 2.7 14 9–17 1.2 ± 1.3 1 0–3
SD — standard deviation; n — number of medications
Qualified success for the target IOP ≤ 18 mm Hg 
criterion was achieved in 86.6% of cases after 
36 months, 85.4% after 48 months, and 81.2% af-
ter 60 months, and for the target IOP ≤ 12 mm Hg 
criterion, the qualified success rate reached 25.7%, 
17.9%, and 8.5%, respectively (Fig. 3).
IOP below 18 mm Hg was achieved in 90.4% 
of cases after 24 months. IOP reduction by at least 
30% relative to initial values was achieved in 63.1% 
of eyes after 24 months (Fig. 4).
additionaL proCedures
5-FU injections were applied in 70 eyes (38.9%). 
The average 5-FU dose was 19.7 ± 12.7 mg (5–75) 
at an average injection dose of 3.9 ± 2.5 mg (1–15). 
The average time until commencement of 5-FU 
therapy was 17.8 ± 10.4 days after surgery (2– 
–44 days).
Goniopuncture was performed in 52 eyes 
(23.7%), and suturolysis was performed in 44 cases 
(20.1%). Suturolysis and goniopuncture were per-
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Figure 4. Scatter plot: x axis — intraocular pressure before surgery and y axis — 24 months after surgery: IOP ≤ 18.0 mm Hg (a);  
IOP reduction ≥ 30% (B)
Figure 3. Cumulative proportion surviving for 12 and 18 mm Hg criteria: qualified success rate (a); complete success rate (B)
formed concurrently in 34 cases (15.6%). Needling 
was performed in 40 eyes (18.3% of all cases).
CorreCted distanCe VisuaL aCuitY
Mean logMAR of BCVA improved from 
0.3 ± 0.3 before surgery to 0.1 ± 0.2 after 24 months 
(P < 0.001). On day 1 after surgery, there was 
a slight decrease of BCVA to 0.4 ± 0.3, but on 
day 7 it improved to 0.3 ± 0.3. On day 30, BCVA 
reached 0.1 ± 0.2 and stabilised until the end of the 
observation period (P = 0.753) (Tab. 3).
At month 24 post-surgery, BCVA was lower by 
0.5 in 20.2% of cases and higher by 0.5 in 79.8% 
of cases. BCVA above 0.8 was achieved in 53.9% 
of treated eyes. Loss of two or more lines of vi-
sion on the Snellen chart was observed in four eyes 
(1.8%) after 12 months and in six eyes (2.7%) after 
24 months.
COMPLICATIONS
Transitory hypotony occurred in 79 eyes (36.1% 
of cases) and was the most frequent post-operative 
a B
a B
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Table 3. Mean values of best corrected distant visual acuity at specific times after surgery
Best corrected distance visual acuity (logMAR)
Time Mean (SD) Range P* P^
Pre-op 0.3 ± 0.3 0–1
1st day 0.4 ± 0.3 0–1 0.026
7th day 0.3 ± 0.3 0–1 0.019
1st month 0.1 ± 0.2 0–1 < 0.001
6th month 0.1 ± 0.2 0–0.8 < 0.001
12th month 0.1 ± 0.1 0–0.5 < 0.001
18th month 0.1 ± 0.2 0–0.7 < 0.001
24th month 0.1 ± 0.2 0–0.7 < 0.001
36th month 0.2 ± 0.1 0–0.5 0.065351
48th month 0.2 ± 0.3 0–1 0.206 0.753
SD — standard deviation; logMAR — logarithm of the minimum angle of resolution; *Wilcoxon matched pairs test; ^Friedman ANOVA, c2 ANOVA = 8,790698
Table 4. Post-operative complications
Post-operative complications n %
Early
Hypotony 79 36.1
Corneal oedema 16 7.3
Anterior chamber shallowing 12 5.5
Blood in the vicinity of the filtering bleb 9 4.1
Serous choroidal detachment 8 3.7
Leaking filtering bleb 6 2.7
Inflammatory cells in anterior chamber 5 2.3
Intraocular pressure rise 4 1.8
Hyphaemia 2 0.9
Orbital haematoma 1 0.5
Late
Bleb fibrosis 48 21.9
Epitheliopathy 25 11.4
Erosion of corneal epithelium 10 4.6
Choroidal membrane 7 3.2
Posterior synechia 5 2.3
Cystoid macular oedema 5 2.3
Posterior capsule opacification 3 1.4
Macular haemorrhage 2 0.9
Peripheral ulcerative keratitis 1 0.5
Delamination of equatorial retina 1 0.5
Transitory astigmatism after 5-FU therapy 1 0.5
Dellen 1 0.5
Haemorrhagic choroidal detachment 1 0.5
Retinal tear 1 0.5
Iris entrapment in the goniopuncture wound 1 0.5
complication. In one case (0.4%), persistent hypo-
tony lasted for three months. Shallowing of the an-
terior chamber occurred in 12 eyes (6.9% of cases), 
and serous choroidal detachment occurred in eight 
cases (3.7% of eyes). The most frequent onset of late 
post-operative complication was filtering bleb fibro-
sis in 48 eyes (21.9%). After subconjunctival 5-FU 
injections, short-term corneal epithelium erosion 
occurred in 25 eyes (11.4%) and transitory astigma-
tism in one eye (0.5%). A compilation of post-oper-
ative complications is presented in Table 4.
disCussion
DS reduces IOP by facilitating filtration of aque-
ous humour through the thin TDM that is left 
behind from the anterior chamber to the intrascleral 
decompression space, and from there to the subcon-
junctival space, suprachoroidal space, and trans-scle-
ral path [4]. In order to improve the success rate of 
surgery, many authors apply post-operative proce-
dures that improve the flow of aqueous humour 
[1, 7–9, 14, 15]. To limit fibrosis of the filtration 
fistula we applied pre-operative 5-FU injections 
more frequently and at a mean dose higher than 
that encountered in the literature [1, 7–9, 14, 15]. 
Only Reinthal et al. applied a greater injection dose 
[16]. The average dose of 5-FU was lower than that 
applied by Reinthal et al. [16]. In most studies, the 
percentage of injections falls within the range from 
20 to 38%, and in our study this percentage reached 
38.9% [1, 7, 9, 15, 17]. 
Shaarawy et al. believe that goniopuncture 
should be recognised as part of the post-operative 
procedure after DS and that earlier goniopuncture 
is more effective over a long-term observation pe-
riod [14, 18, 19]. We have applied goniopuncture 
somewhat less frequently than as described in the 
literature and we did not carry out prophylactic 
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localised argon iridoplasty [14, 15, 18–20]. Iris in-
carceration into the scleral lake is observed as the 
most common complication after goniopuncture 
[20]. We noticed it in one eye only. The possi-
ble cause is that all our cases were combined with 
a phacoemulsification. Another reason could be 
the presence of SkGel, which occupies the scle-
ral lake and prevents a sudden decompression. 
The subconjunctival outflow is the most impor-
tant functional drainage pathway for aqueous hu-
mour in the first month after surgery, which is 
why we also applied eye massage after the perfor-
mance of laser goniopuncture in this period [9]. 
Suturolysis is rarely applied after non-penetrating 
procedures [21]. In our observations, it was applied 
relatively often and generally in combination with 
goniopuncture in order to reduce resistance as much 
as possible on the route of aqueous humour drain-
age. Only Funnelli et al. reported a lower frequency 
of its application [21]. We combined post-operative 
needling with simultaneous 5-FU injection, similar-
ly to Bissig et al. [22]. 
Guedes et al. did not observe a significant dif-
ference in the post-operative success rate between 
the non-penetrating procedure and its combination 
with phacoemulsification [23]. Average IOP reduc-
tion, both short-term and medium-term, achieved 
by other authors is comparable to the reduction 
achieved in our study [6, 24, 25]. Only long-term 
IOP reduction after 60 months was slightly lower 
in our study (33.2%) than in the study by Galassi et 
al. (37.65%) [18]. Application of mitomycin during 
surgery by Russo et al. did not have a significant 
effect on increasing the percentage of IOP reduction 
(38.3%) [26]. Reduction of applied medications was 
similar to that seen in the study by Rebolleda et al. 
but lower than in the study by Galassi et al. [18, 24]. 
Post-operative BCVA is dependent on the 
rate of intra and post-operative complications as 
well as induced corneal astigmatism [27]. Shoji 
et al. showed that combining cataract surgery and 
non-penetrating surgery does not have a negative 
effect on post-operative BCVA in comparison 
with phacoemulsification by itself [28]. Our study 
shows, similarly as in the majority of other studies, 
that after a slight reduction in the initial post-op-
erative period, the BCVA after DS returned to the 
baseline level after one week and stabilised around 
the third month [7–9, 14, 28, 29]. During the in-
itial 24th month observation period, the mean log-
MAR value of BCVA was 0.1 ± 0.2. A loss of two 
or more lines on the Snellen chart was observed in 
six eyes (2.7%) after 24 months. Subretinal macular 
haemorrhage occurred in two eyes (0.9%), folding 
of the premacular membrane occurred in two eyes 
(0.9%), and chronic cystoid macular oedema oc-
curred in two eyes (0.9%).
The most frequent early complication was tran-
sitory hypotony (36.1%). Other authors noted an 
equally quick disappearance of hypotony [7]. More-
over, on the first day after surgery, it was recognised 
by Shaarawy et al. as a positive factor in prognosis 
because it improved post-operative success and re-
duced the number of additional procedures stabilis-
ing drainage paths [30]. 
We observed inflammatory cells in a lower per-
centage (2.3%) than other authors (27.29%), which 
is the effect of preservation of the integrity of the 
anterior chamber [1, 31]. Shaarawy et al. believe that 
a small amount of blood in the anterior chamber in 
the early post-operative period is probably the result 
of a blood reflux from the produced scleral bed [8]. 
Bleeding into the anterior chamber that ceased with-
out consequence was observed in 0.9% of eyes. In 
most studies, bleeding into the anterior chamber 
does not exceed the teens in terms of percentage, and 
blood is quickly absorbed [9, 10, 21, 24]. 
Raised IOP in the early post-operative period 
occurred in 1.8% of cases; this percentage was lower 
than that encountered by other authors [30, 32]. 
The application of goniopuncture and delicate eye 
massage made it possible to control IOP in three 
eyes; however, one case required the introduction 
of anti-glaucoma medications. In one eye, TDM 
rupture and iris entrapment requiring surgical inter-
vention took place after goniopuncture.
We observed fibrosis of the filtering bleb at 
a similar rate of occurrence as did Mermoud et al. 
and Kozobolis et al. [1, 17]. Retinal delamination 
appeared in one patient, and equatorial retinal tear-
ing occurred in another and was resolved by laser 
treatment. The low percentage of complications of 
this type after DS procedures is consistent with the 
results of other authors [1, 10, 32]. 
Clouding of the posterior capsule requiring laser 
capsulotomy took place in three eyes (1.4%). An 
extra-orbital haematoma occurred in one patient 
(0.5%) during extra-orbital anaesthesia; however, it 
subsided without side effects.
ConCLusions
Long-term follow-up demonstrate that non-pen-
etrating phaco-deep sclerectomy with SkGel im-
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plantation combined with cataract surgery has the 
potential to achieve an effective reduction of IOP 
over the course of long-term follow-up. However, 
some of the early reduction diminished over time 
due to the progressing regeneration taking place in 
the sclera and episcleral space. The applied proce-
dures for re-establishing drainage pathways are an 
integral component of post-operative care. These are 
necessary when aggressive healing limits the effect of 
the conducted surgery. The profile of the observed 
complications and significant improvement of 
visual acuity in the majority of eyes provide grounds 
for recognising non-penetrating deep sclerectomy 
as a safe procedure in patients with glaucoma and 
co-existing cataract.
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